The study, led by researchers at New York University College of Dentistry in New York City and Queen’s University in Ontario, found that novel opioid NFEPP can treat inflamed tissue in mice while sparing healthy tissue.
This discovery means patient recovery could bypass the severe and life-threatening side effects of opioids, such as difficulty breathing, constipation, sedation and addiction.
Researchers are now collecting tissue samples from people with inflammatory bowel disease to determine whether their colons, like those in mice, are also acidic environments. They plan to test NFEPP’s ability to inhibit pain in the human gut and ultimately conduct clinical trials.
More articles on surgery centers:
15 ASCs opened or announced in March
CEO predicts Biden’s $1.9 trillion plan will help ASCs
ASCs return to growth: Big plans from innovative execs
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.